Overview
Bigfoot Biomedical provides a subscription-based digital drug delivery platform for insulin management, delivered through partnerships with healthcare providers. The platform combines patient-facing tools with remote physiologic monitoring to track glucose, insulin usage, and other health data, offering ongoing support and services rather than a one-time product. It integrates with provider workflows to enable RPM, allowing clinicians to monitor patients remotely and adjust therapy as needed. The company differs from competitors by focusing on a service-based, provider-centered approach that emphasizes simplicity, accessibility, and health equity, backed by Silicon Valley expertise. Its goal is to reduce the daily burden of diabetes, broaden access to effective insulin management, and help healthcare providers deliver optimal care.
Work here?Claim your company
Simplify's take
What believers are saying
- Bigfoot reported smartloop AID trial enrollment across Stanford, Sansum, and Colorado in 2026.
- Abbott's 2026 diabetes portfolio gives Bigfoot distribution, manufacturing, and reimbursement muscle.
- Connected insulin ecosystems fit payers demanding fewer hypoglycemia events and richer remote monitoring.
What critics are saying
- Abbott completed Bigfoot's acquisition in 2023, eliminating independent strategic control.
- Smartloop still depends on FDA approval and multi-site trial execution before commercialization.
- Abbott can shelve Bigfoot's roadmap entirely, killing the standalone brand.
What makes Bigfoot Biomedical unique
- Abbott owns Bigfoot's smart insulin pen-cap IP and connected diabetes workflow since 2023.
- Bigfoot Unity remains the first FDA-cleared connected insulin pen-cap system.
- Its CGM-linked dosing recommendations tie sensors, pen caps, and clinician instructions together.
Help us improve and share your feedback! Did you find this helpful?